Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus

被引:87
作者
Mazarati, AM [1 ]
Baldwin, R
Klitgaard, H
Matagne, A
Wasterlain, CG
机构
[1] Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA
[2] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA
[3] UCB Bioprod SA, Pharma Sector, Preclin CNS Res, Braine LAlleud, Belgium
[4] Univ Calif Los Angeles, Geffen Sch Med, Brain Res Inst, Los Angeles, CA USA
关键词
status epilepticus; levetiracetam; diazepam; experimental model;
D O I
10.1016/j.eplepsyres.2004.02.002
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Status epilepticus (SE) is a neurological emergency, with high mortality and high morbidity among survivors, and novel therapeutic agents are needed to improve this picture. We examined the effects of the antiepileptic drug levetiracetam (LEV) in an experimental model Of Self-sustaining status epilepticus (SSSE), induced in rats by electrical stimulation of the perforant path. LEV's unique spectrum of anticonvulsant activity, very high therapeutic index, and neuroprotective properties, make it a potentially interesting agent in the treatment of SE. Pretreatment with LEV intravenously reduced (30 mg/kg) or prevented (50-1000 mg/kg) the development of self-sustaining seizures. Treatment during the maintenance phase of SSSE diminished (at 200 mg/kg) or aborted seizures (in doses of 500 or 1000 mg/kg). Addition of LEV significantly enhanced the anticonvulsant effects of diazepam (DZP), even when both drugs where given in doses far below their therapeutic level. We conclude that LEV deserves further evaluation in the treatment of status epilepticus. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:167 / 174
页数:8
相关论文
共 30 条
[1]   Levetiracetam for partial seizures - Results of a double-blind, randomized clinical trial [J].
Cereghino, JJ ;
Biton, V ;
Abou-Khalil, B ;
Dreifuss, F ;
Gauer, LJ ;
Leppik, I .
NEUROLOGY, 2000, 55 (02) :236-242
[2]  
DELORENZO RJ, 1995, J CLIN NEUROPHYSIOL, V12, P316
[3]   A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia [J].
DeLorenzo, RJ ;
Hauser, WA ;
Towne, AR ;
Boggs, JG ;
Pellock, JM ;
Penberthy, L ;
Garnett, L ;
Fortner, CA ;
Ko, D .
NEUROLOGY, 1996, 46 (04) :1029-1035
[4]   A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy [J].
Doheny, HC ;
Whittington, MA ;
Jefferys, JGR ;
Patsalos, PN .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (06) :1425-1434
[5]   Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy [J].
Glien, M ;
Brandt, C ;
Potschka, H ;
Löscher, W .
EPILEPSIA, 2002, 43 (04) :350-357
[6]   Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy [J].
Gower, AJ ;
Hirsch, E ;
Boehrer, A ;
Noyer, M ;
Marescaux, C .
EPILEPSY RESEARCH, 1995, 22 (03) :207-213
[7]  
HANON E, 2000, SEIZURE, V10, P287
[8]   Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy [J].
Klitgaard, H ;
Matagne, A ;
Gobert, J ;
Wülfert, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) :191-206
[9]   Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy [J].
Klitgaard, H ;
Matagne, A ;
Grimee, R ;
Vanneste-Goemaere, J ;
Margineanu, DG .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2003, 12 (02) :92-100
[10]   Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? [J].
Klitgaard, H .
EPILEPSIA, 2001, 42 :13-18